vs
Nurix Therapeutics, Inc.（NRIX）与Rumble Inc.（RUM）财务数据对比。点击上方公司名可切换其他公司
Rumble Inc.的季度营收约是Nurix Therapeutics, Inc.的2.0倍（$27.1M vs $13.6M），Rumble Inc.净利率更高（-120.8% vs -576.1%，领先455.3%），Nurix Therapeutics, Inc.同比增速更快（2.2% vs -10.5%），Rumble Inc.自由现金流更多（$-31.7M vs $-73.0M），过去两年Rumble Inc.的营收复合增速更高（15.2% vs -9.5%）
Nurix Therapeutics是一家临床阶段生物制药企业，专注于发现、开发及商业化针对癌症、免疫疾病等存在重大未满足医疗需求的新型靶向蛋白降解疗法，依托专有的E3泛素连接酶调节技术推进管线研发，与全球多家制药企业达成合作。
Rumble Inc.是一家加美跨国企业，主营在线视频平台、网络托管及云服务，总部位于加拿大多伦多，美国总部设在佛罗里达州朗博特基。公司由加拿大科技创业者克里斯·帕夫洛夫斯基于2013年创立，云服务板块为Truth Social提供托管支持，其视频平台在美国保守派及极右翼用户群体中广受欢迎，属于“另类科技”阵营。
NRIX vs RUM — 直观对比
营收规模更大
RUM
是对方的2.0倍
$13.6M
营收增速更快
NRIX
高出12.7%
-10.5%
净利率更高
RUM
高出455.3%
-576.1%
自由现金流更多
RUM
多$41.2M
$-73.0M
两年增速更快
RUM
近两年复合增速
-9.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $13.6M | $27.1M |
| 净利润 | $-78.2M | $-32.7M |
| 毛利率 | — | 5.5% |
| 营业利润率 | -612.0% | -131.1% |
| 净利率 | -576.1% | -120.8% |
| 营收同比 | 2.2% | -10.5% |
| 净利润同比 | -33.6% | 86.2% |
| 每股收益（稀释后） | $-0.83 | $-0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NRIXRUM
| Q4 25 | $13.6M | $27.1M | ||
| Q3 25 | $7.9M | $24.8M | ||
| Q2 25 | $44.1M | — | ||
| Q1 25 | $18.5M | $23.7M | ||
| Q4 24 | $13.3M | $30.2M | ||
| Q3 24 | $12.6M | $25.1M | ||
| Q2 24 | $12.1M | $22.5M | ||
| Q1 24 | $16.6M | $17.7M |
净利润NRIXRUM
| Q4 25 | $-78.2M | $-32.7M | ||
| Q3 25 | $-86.4M | $-16.3M | ||
| Q2 25 | $-43.5M | — | ||
| Q1 25 | $-56.4M | $-2.7M | ||
| Q4 24 | $-58.5M | $-236.8M | ||
| Q3 24 | $-49.0M | $-31.5M | ||
| Q2 24 | $-44.5M | $-26.8M | ||
| Q1 24 | $-41.5M | $-43.3M |
毛利率NRIXRUM
| Q4 25 | — | 5.5% | ||
| Q3 25 | — | -1.8% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -26.7% | ||
| Q4 24 | — | -14.2% | ||
| Q3 24 | — | -45.4% | ||
| Q2 24 | — | -58.8% | ||
| Q1 24 | — | -79.5% |
营业利润率NRIXRUM
| Q4 25 | -612.0% | -131.1% | ||
| Q3 25 | -1157.7% | -113.6% | ||
| Q2 25 | -109.7% | — | ||
| Q1 25 | -340.7% | -153.5% | ||
| Q4 24 | -486.7% | -80.1% | ||
| Q3 24 | -433.8% | -131.0% | ||
| Q2 24 | -401.4% | -172.7% | ||
| Q1 24 | -272.6% | -197.4% |
净利率NRIXRUM
| Q4 25 | -576.1% | -120.8% | ||
| Q3 25 | -1094.8% | -65.7% | ||
| Q2 25 | -98.7% | — | ||
| Q1 25 | -305.4% | -11.2% | ||
| Q4 24 | -440.7% | -783.2% | ||
| Q3 24 | -388.9% | -125.9% | ||
| Q2 24 | -368.4% | -119.2% | ||
| Q1 24 | -250.3% | -244.1% |
每股收益（稀释后）NRIXRUM
| Q4 25 | $-0.83 | $-0.13 | ||
| Q3 25 | $-1.03 | $-0.06 | ||
| Q2 25 | $-0.52 | — | ||
| Q1 25 | $-0.67 | $-0.01 | ||
| Q4 24 | $-0.74 | $-1.17 | ||
| Q3 24 | $-0.67 | $-0.15 | ||
| Q2 24 | $-0.71 | $-0.13 | ||
| Q1 24 | $-0.76 | $-0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $247.0M | $237.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $538.7M | $274.8M |
| 总资产 | $688.1M | $336.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NRIXRUM
| Q4 25 | $247.0M | $237.9M | ||
| Q3 25 | $78.4M | $269.8M | ||
| Q2 25 | $84.3M | — | ||
| Q1 25 | $75.9M | $301.3M | ||
| Q4 24 | $110.0M | $114.0M | ||
| Q3 24 | $99.0M | $132.0M | ||
| Q2 24 | $116.8M | $154.2M | ||
| Q1 24 | $49.8M | $183.8M |
股东权益NRIXRUM
| Q4 25 | $538.7M | $274.8M | ||
| Q3 25 | $372.3M | $302.2M | ||
| Q2 25 | $447.6M | — | ||
| Q1 25 | $480.9M | $339.6M | ||
| Q4 24 | $527.0M | $-63.1M | ||
| Q3 24 | $376.9M | $166.1M | ||
| Q2 24 | $370.7M | $192.7M | ||
| Q1 24 | $168.7M | $210.7M |
总资产NRIXRUM
| Q4 25 | $688.1M | $336.8M | ||
| Q3 25 | $522.5M | $367.2M | ||
| Q2 25 | $591.6M | — | ||
| Q1 25 | $615.0M | $391.1M | ||
| Q4 24 | $669.3M | $195.3M | ||
| Q3 24 | $513.6M | $217.2M | ||
| Q2 24 | $511.0M | $243.2M | ||
| Q1 24 | $312.7M | $263.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-67.8M | $-29.4M |
| 自由现金流经营现金流 - 资本支出 | $-73.0M | $-31.7M |
| 自由现金流率自由现金流/营收 | -537.4% | -117.2% |
| 资本支出强度资本支出/营收 | 37.8% | 8.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-263.5M | $-70.8M |
8季度趋势，按日历期对齐
经营现金流NRIXRUM
| Q4 25 | $-67.8M | $-29.4M | ||
| Q3 25 | $-57.4M | $-10.6M | ||
| Q2 25 | $-63.2M | — | ||
| Q1 25 | $-61.1M | $-14.5M | ||
| Q4 24 | $-48.8M | $-12.4M | ||
| Q3 24 | $-42.2M | $-19.1M | ||
| Q2 24 | $-39.7M | $-21.7M | ||
| Q1 24 | $-42.0M | $-33.9M |
自由现金流NRIXRUM
| Q4 25 | $-73.0M | $-31.7M | ||
| Q3 25 | $-60.1M | $-12.0M | ||
| Q2 25 | $-65.8M | — | ||
| Q1 25 | $-64.6M | $-14.6M | ||
| Q4 24 | $-50.9M | $-12.4M | ||
| Q3 24 | $-44.5M | $-19.9M | ||
| Q2 24 | $-41.6M | $-23.1M | ||
| Q1 24 | $-44.8M | $-34.3M |
自由现金流率NRIXRUM
| Q4 25 | -537.4% | -117.2% | ||
| Q3 25 | -761.3% | -48.6% | ||
| Q2 25 | -149.4% | — | ||
| Q1 25 | -349.9% | -61.7% | ||
| Q4 24 | -382.8% | -40.9% | ||
| Q3 24 | -353.7% | -79.5% | ||
| Q2 24 | -344.4% | -102.8% | ||
| Q1 24 | -270.3% | -193.3% |
资本支出强度NRIXRUM
| Q4 25 | 37.8% | 8.5% | ||
| Q3 25 | 34.3% | 5.7% | ||
| Q2 25 | 6.1% | — | ||
| Q1 25 | 18.9% | 0.6% | ||
| Q4 24 | 15.8% | 0.1% | ||
| Q3 24 | 18.6% | 3.4% | ||
| Q2 24 | 16.0% | 6.1% | ||
| Q1 24 | 17.4% | 2.4% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NRIX
| Pfizer | $11.9M | 88% |
| Gilead Agreement | $1.7M | 13% |
RUM
| Audience Monetization | $23.8M | 88% |
| Other Initiatives | $3.3M | 12% |
